Bayer sticks by Xarelto sales estimate despite study setback

31

FRANKFURT/BERLIN (Reuters) – Bayer stood by its peak sales estimate for clot prevention drug Xarelto after the pill disappointed in a late-stage trial to test prevention of repeat strokes.
Source : http://in.reuters.com/